Genetronics' CE-marks electroporation device:
This article was originally published in Clinica
Executive Summary
Genetronics Biomedical has CE-marked its MedPulser electroporation device used in the treatment of solid tumours. The product provides electrical pulses to the tumour, causing the cell pores to open temporarily. This allows the delivery of the chemotherapy drug bleomycin to the cancer site. The CE-marking triggers a milestone payment from Ethicon, Genetronics' marketing partner.